Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72 USD | -6.12% | +5.93% | +0.53% |
Apr. 18 | Intra-Cellular Therapies Prices $500 Million Stock Offering | MT |
Apr. 17 | Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating | MT |
Business Summary
Number of employees: 610
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Drugs
100.0
%
| 250 | 100.0 % | 464 | 100.0 % | +85.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 250 | 100.0 % | 464 | 100.0 % | +85.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
Director of Finance/CFO | 67 | 13-08-28 | |
Michael Halstead
PSD | President | 51 | 14-06-30 |
Willie Earley
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Suresh Durgam
CTO | Chief Tech/Sci/R&D Officer | - | - |
Karen Sheehy
CMP | Compliance Officer | 62 | 19-07-01 |
Robert Davis
CTO | Chief Tech/Sci/R&D Officer | 73 | 15-10-31 |
Juan F. Sanchez
IRC | Investor Relations Contact | - | 14-03-09 |
John A. Bardi
LAW | General Counsel | - | 19-03-25 |
General Counsel | - | 18-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 14-01-07 |
Joel Marcus
BRD | Director/Board Member | 76 | 13-08-28 |
Director/Board Member | 67 | 14-01-07 | |
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
Rene Salas
BRD | Director/Board Member | 62 | 22-04-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 97,477,818 | 94,938,814 ( 97.40 %) | 0 | 97.40 % |
Company contact information
Intra-Cellular Therapies, Inc.
430 East 29th Street Suite 900
10016, New York
+646 440 9333
http://www.intracellulartherapies.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.53% | 7.51B | |
-6.21% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+52.09% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-2.85% | 8.07B |
- Stock Market
- Equities
- ITCI Stock
- Company Intra-Cellular Therapies, Inc.